Edesa Biotech, Inc. Key Metrics

8 years of history · ending 2021-09-30 · SEC EDGAR

Forensics

Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.

F-Score (Piotroski 0-9)

Z-Score (Altman; <1.81 = distress)

Per Share Metrics

Turnover & Efficiency Analysis (days)

Expense Ratios

Working Capital Analysis

Valuation Multiples

Enterprise Value Multiples

52-Week Range

Trailing Returns

ROIC vs WACC

Yields

Capital Deployment Yields

Liquidity & Leverage Ratios

Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)

EPS (Diluted)
$-1
Book Value Per Share
$1
Free Cash Flow Per Share
$-1
Cash Per Share
$1
Revenue Per Share
$0
OCF Per Share
$-1
Return on Equity↓-84.5pts
-135.5%
Return on Assets↓-56.6pts
-105.3%
Return on Invested Capital↓-148.2pts
-190.0%
Current Ratio↓-60.6% -$13
8.29
Quick Ratio↓-60.2% -$13
8.29
Asset Turnover↓-100.0% -$0
0.00
Days Sales Outstanding
54.65
Days Inventory On Hand
614.01
R&D / Revenue↑+876.6pts
1012.6%
SBC / Revenue↑+161.6pts
182.0%
Capex / Revenue↓-30.2pts
1.5%
Working Capital↑+65.2% +$4M
$11M
Net Current Asset Value↑+56.3% +$4M
$11M
Invested Capital↑+76.5% +$6M
$13M
OCF / Net Income↑+9.6% +$0
1.02
FCF / Net Income↑+3.0% +$0
1.02
Accruals Ratio (Sloan)↑+6.5pts
2.2%
Net Debt↓-19.4% -$1M
$-8M
Net Debt / EBITDA↓-74.4% -$1
0.33
Capex Coverage↓-14222.2% -$2K
-2223.39
Tangible Common Equity↑+44.3% +$3M
$11M
TCE / Total Assets↓-22.6pts
73.2%
NOPAT↓-353.3% -$15M
$-19M
Cash ROIC↓-88.1pts
-138.9%
WC / Revenue↑+1097.0pts
1999.4%
Capex / D&A↓-96.9% -$2
0.05
Reinvestment Rate↑+2.8pts
0.5%
Asset Growth vs Revenue Growth↑+93.8pts
135.5%
Revenue 5Y CAGR
-15.4%
Book Value 5Y CAGR↓-51.1pts
1.2%
Stock Price (FY-end)↓-84.5% -$281
$52
Market Cap
$6.23B
P/S Ratio
4897.30
P/B Ratio
505.75
P/TB Ratio
505.75
Enterprise Value
$6.22B
EV / Sales
4888.33
FCF Yield
-0.1%
Shareholder Yield
-0.0%
R&D Yield
0.0%
Capex Yield
0.0%
Shares Variation (YoY)
10.9%
Beta (5Y)↑+5.3% +$0
0.67
Cost of Equity↑+0.2pts
7.8%
52W High↓-88.6% -$652
$83
52W Low↓-91.0% -$297
$29
Trailing Return 1Y↑+45.3pts
-8.6%
Trailing Return 5Y
-92.8%
F-Score (Piotroski)↓-50.0% -$1
1.00
Z-Score (Altman)
3768.18

Earnings Forecasts

Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).

Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.

EPS — Consensus vs Actual

Stock Price on Earnings Dates

Edesa Biotech, Inc. — Effective Tax Rate ReconciliationNEW

Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.

Reconciliation LineFY2020FY2021FY2022FY2023FY2024FY2025
Federal Statutory Rate26.50%26.50%26.50%26.50%26.50%26.50%
State & Local Income Taxes
Foreign Rate Differential
Other Adjustments
Effective Tax Rate

Cash vs Accrual

ItemFY2020FY2021FY2022FY2023FY2024FY2025
Income Tax Expense (Accrual)$800$800$800$800$800$800
Income Taxes Paid (Cash)